ProteoNic and Oxford Expression Technologies sign UNic™ license for use in flashBAC™

Leiden, Netherlands/Oxford, United Kingdom, March 7, 2013 – Dutch biotech company ProteoNic BV and Oxford Expression Technologies Ltd (OET), a leading provider of baculovirus-based protein expression products and services, have extended their partnership by signing a commercial license agreement. OET obtains the right to use ProteoNic’s UNic™ translation enhancing elements in its flashBAC™ system for third party recombinant protein production services. ProteoNic will provide technical support. Financial terms include upfront and royalty payments.

ProteoNic announces closing of financing round

Leiden, The Netherlands, September 28, 2011 – Dutch biotech company ProteoNic B.V. announces successful completion of a € 6 mln equity financing round led by US-based Fairbanks Investment Fund (FIF), with existing shareholders participating. The funding will be used to accelerate commercialization of ProteoNic’s proprietary UNic™ recombinant protein yield enhancement technology and expand the company’s capabilities in the area of cell line generation and contract services.

ProteoNic and Oxford ET join forces combining UNic™ with flashBAC™ protein expression platform

March 8, 2011 – Leiden, Netherlands/Oxford, United Kingdom – ProteoNic BV, the protein production experts, and Oxford Expression Technologies Ltd (OET), a leading provider of baculovirus-based protein expression products and services, have joined forces in the field of recombinant protein production technology with the aim of jointly offering a superior platform and services. Several projects combining ProteoNic’s UNic™ translation enhancement elements with OET’s flashBAC™ system have been initiated.

European grant for ProteoNic and ORYZON

ProteoNic and ORYZON awarded European grant for joint development of cost-effective therapeutic antibodies against prostate cancer.

Leiden, Netherlands/Barcelona, Spain – ProteoNic, the protein production experts, and ORYZON genomics, the biomarker discovery company, have joined forces to develop new antibodies against prostate cancer and generate cost-effective production-ready cell lines. ProteoNic will use its expression expertise and UNic™ toolbox production yield enhancer to optimize the potential of ORYZON’s proprietary targets without compromising antibody quality. By awarding the joint venture a EuroTrans-Bio grant, the EU recognizes the unique combination of skills that will serve an unmet medical need for new prostate cancer diagnostics and treatment.

ProteoNic Receives Prestigious Frost & Sullivan Technology Innovation Award

Leiden – ProteoNic, the protein expression experts, has been awarded the Frost & Sullivan 2010 European Food Enzymes Technology Innovation Award. Frost & Sullivan recognised the company’s important contribution to cost and energy reductions in food enzyme manufacturing. It also praised its innovative technologies for enhancing production efficiency, providing the flexibility for researchers and companies to prospect nature and develop novel protein products and aid higher protein yields in a wide range of manufacturing processes.

ProteoNic and Novozymes Sign Agreement for UNic™ yield enhancer

Leiden, 14 December 2009 – ProteoNic, the protein expression experts, and Novozymes, the global leader in industrial enzymes and microorganisms, have signed an agreement in which Novozymes gains the right to use ProteoNic’s UNic™ expression toolbox and specifically UNic-FTee™ for one of its leading enzyme products. Novozymes has also taken an option to license UNic-FTee™ for commercial production.

ProteoNic and TNO Sign License Agreement

ProteoNic, the protein expression experts, announces
it has entered into a license agreement with the research organization TNO. Last year the parties formalized their collaboration on improving the expression yields of mammalian host systems using the ProteoNic proprietary UNic™ toolbox. In the past year the UNic-MTee™ (one of ProteoNic’s Translation Enhancement Element products) has proven successful in commercial production conditions using suspension CHO cells and serum free medium. TNO therefore, decided to obtain a commercial license for the production of modified pro-urokinase detection enzymes for use in its proprietary QuickZyme technology platform. The financial details of this deal were not disclosed.

ProteoNic and Genencor Sign Research Agreement

ProteoNic, the protein expression experts, and Genencor, a Danisco Division, have signed a research agreement. As part of the contract, the two biotech companies will use ProteoNic’s UNic™ Toolbox to investigate enzyme production for Genencor’s fungal expression platforms. ProteoNic will support Genencor in applying the unique protein yield enhancement products.